GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Fredun Pharmaceuticals Ltd

Fredun Pharmaceuticals Board Approves Q2 FY27 Results, NSE Listing Application

RESULTS ● No Immediate Change LOW RISK
📅 Filed on BSE: 05 Nov 2026, 11:31 AM IST  ·  BSE ID: 17121e58-6df8-4104-b02e-bc9599b6da9f
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's board approved its latest financial results and decided to apply for its shares to be listed on the NSE.
🤖 AI Summary
  • Fredun Pharmaceuticals Board approved unaudited financial results for Q2 FY27 and half-year ended September 30, 2026.
  • Board approved application to National Stock Exchange of India Limited (NSE) for listing of equity shares.
  • Financial results for the period were reviewed by Statutory Auditor M/s. R.H. Nisar & Co.
  • The Board meeting, held November 05, 2026, commenced at 10:00 a.m. and concluded at 11:10 a.m.
🏢 How This Affects the Company
📈
Business Impact
The approval to apply for NSE listing could broaden the company's investor base and visibility in the capital markets, potentially facilitating future capital raising efforts.
💰
Financial Impact
The filing reports the approval of financial results, but the specific financial figures themselves are not included in this document, thus preventing detailed financial impact analysis at this stage.
⚠️
Risk Impact
Applying for an NSE listing involves regulatory processes and approvals. The success of the application and the subsequent listing will depend on fulfilling all stipulated requirements.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this specific filing.
👤
Who Is Affected
Existing shareholders will be affected by the potential NSE listing, which could lead to increased trading avenues for the company's shares.
🔍
Management Signal
Management's decision to pursue NSE listing signals an intent to expand its public market presence and potentially broaden its shareholder base.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Review of the full Q2 FY27 financial results to assess performance metrics.
Announcement regarding the status and timeline of the NSE listing application.
Future updates on the company's financial and operational performance.
LOW RISK The filing reports board approvals and an application, without immediate new risks.
💡 Investor Takeaway
Fredun Pharmaceuticals' board has approved its Q2 FY27 and half-year financial results for the period ended September 30, 2026. The company also decided to apply for listing and trading of its equity shares on the National Stock Exchange of India Limited.
⚖️ Strengths & Concerns

✅ Positives

  • Board approval of half-yearly financial results ensures timely compliance with SEBI Regulation 33 requirements.
  • Decision to apply for NSE listing indicates management's intent to enhance market access and liquidity for its shares.
📅 Company Track Record
Fredun Pharmaceuticals' Board approved its Q1 FY27 Un-Audited Financial Results on August 05, 2026, in compliance with SEBI Regulations 30 and 33, similar to this current filing for Q2 FY27.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What financial period do these Fredun Pharmaceuticals results cover?
The financial results approved by the Board cover the Quarter and Half-Year Ended 30th September, 2026, which corresponds to Q2 FY27.
What significant decision did Fredun Pharmaceuticals' Board make?
The Board considered and approved the proposal for making an application to the National Stock Exchange of India Limited (NSE) for listing and trading of the company's equity shares.
Who reviewed the financial results of Fredun Pharmaceuticals?
The Un-Audited Financial Results of Fredun Pharmaceuticals for the Quarter and Half-Year Ended 30th September, 2026, were reviewed by M/s. R.H. Nisar & Co, Statutory Auditor.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.